Alluvi, formerly BI 4744, represents a promising advance in weight control therapy. This dual activator targeting both glucagon-like peptide-1 and GIP sites demonstrates compelling results in patient studies, https://natural-bookmark.com/story22081160/alluvi-a-in-depth-dive-into-the-medication-s-potential